Chembio Diagnostics Reports Second Quarter 2019 Financial Results

Ads

You May Also Like

Rexahn Announces $7.5 Million Registered Direct Offering

ROCKVILLE, Md., Oct. 17, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN) ...

Mersana Presents Interim Dose-Escalation Data on XMT-1522 in Select Cancers at ASCO 2018

Favorable Tolerability Profile and Early Signs of Efficacy Demonstrated First Disclosure of Clinical Data ...